2 news items
Celularity Abstract "Emerging Technologies for the Management and Protection of Tendon Injuries: Decellularized Placental Biomaterials" Accepted at ORS Tendon Conference 2024
CELU
18 Apr 24
a market size of USD 4.8 billion by 2032, growing at a CAGR of 7.6% from 2023 to 2032. We are committed to to growing our
Celularity Submits Request to U.S. FDA for Orphan Drug Designation for PDA-002 Asset Treating Facioscapulohumeral Muscular Dystrophy
CELU
20 Mar 24
percent of patients at risk of wheelchair use within six years of their diagnosis. "Celularity is committed to developing best
- Prev
- 1
- Next